PRINSTON ANNOUNCES THE FDA APPROVAL OF FENOFIBRATE TABLETS, 48mg and 145mg

Prinston is proud to announce its FDA approval for Fenofibrate tablets, 48 mg and 145 mg, which is an AB-rated equivalent to Tricor® by Abbvie.

Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. According to IQVIA, total market sales for Fenofibrate tablets for the last twelve months ending January 2019 were $91.1 million.